HPC/AI Infrastructure and Strategy - Bitfarms has a 1.9 GW power infrastructure asset portfolio in high-demand HPC/AI regions in North America, located in cool climates for improved efficiency[24] - The company is developing 18 MW of HPC/AI infrastructure at its Washington site for Nvidia Blackwell in 2026, with a secured supply chain for $128 million[26, 28] - Panther Creek in Eastern Pennsylvania is planned as a flagship HPC/AI campus with over 410 MW of power and 316 acres of land, with Phase 1 (50 MW) expected in H1 2027 and Phase 2 (300 MW) in H2 2027[33, 34] - Bitfarms has 170 MW of hydropower operating across multiple sites in Quebec, with potential to convert BTC mining infrastructure to HPC/AI[38] - Scrubgrass is a potential gigacampus site with 1.3 GW capacity and 650 acres, offering proximity to Pittsburgh and Cleveland[39, 40] Financial Performance and Capitalization - Bitfarms reported ~$8 million in monthly free cash flow from BTC mining operations in Q3 2025[49] - Q3 2025 revenue was $69 million, a 11% increase Q/Q and a 900% increase Y/Y[51] - Adjusted EBITDA for Q3 2025 was $20 million, a 122% increase Q/Q[51] - The company has over $1 billion in cash and Bitcoin on hand, with remaining funds available from the Macquarie facility[55] Strategic Initiatives - Bitfarms is undergoing a U S pivot, with the majority of planned MW development based in the U S , a new NYC office, and a transition to U S GAAP accounting, aiming for U S redomicile in 2026[42] - The company is evaluating a cloud monetization strategy for its Washington site to replace BTC mining cash flows[42]

Corporate Overview - As of September 30, 2025, Aldeyra's cash, cash equivalents, and marketable securities totaled $75.3 million, expected to fund the company into the second half of 2027[7] - Aldeyra is developing reproxalap for dry eye disease and allergic conjunctivitis, ADX-248 for obesity/hypertriglyceridemia and CNS/Neuroinflammatory Disease, ADX-246 for Dry Age-Related Macular Degeneration/Geographic Atrophy, and ADX-2191 for Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa[6] RASP Modulation and ADX-629 - Reactive Aldehyde Species (RASP) modulation represents a novel pharmacology that may allow for control of protein systems, without turning any single protein on or off[16] - ADX-629, a first-generation RASP modulator, demonstrated activity in Phase 2 clinical trials, including statistically significant changes in lipid profiles (HDL, LDL/HDL ratio, FFA) and reduction of C-Reactive Protein in Alcohol-Associated Hepatitis[21, 29, 35] ADX-246 and ADX-248 - ADX-246, by binding the RASP retinaldehyde, potentially represents a new intravitreally administered therapy for the treatment of Dry Age-Related Macular Degeneration (Dry AMD), showing a reduction in toxic retinaldehyde metabolite A2E in an Abcr Knockout Mouse model[41, 42] - ADX-248, by binding HNE, a pro-inflammatory RASP, potentially represents a new orally administered therapy for the treatment of immune-mediated disease, demonstrating cytokine reduction in LPS-Challenged Mice and improved Epidermal Erosion Score in an Oxazolone Mouse Model of Atopic Dermatitis[44, 45] - ADX-248 significantly improved Rotarod Performance and Grip Strength in the Mouse MPTP Parkinson's Disease Model, as well as Wire Hang Time in the Rat 6-OHDA Parkinson's Disease Model[61, 69] - ADX-248 significantly improved Grip Strength and Rotarod Performance in the Mouse SOD1-G93A Amyotrophic Lateral Sclerosis Disease Model[72] Reproxalap - Reproxalap represents a novel potential therapeutic approach in Dry Eye Disease with rapid activity observed in clinical trials, with a PDUFA Target Action Date of December 16, 2025[85, 89] - The Phase 3 Dry Eye Chamber Trial achieved the primary endpoint of ocular discomfort (P=0.002 for Prespecified Analysis and P=0.004 for Post-Hoc Treatment Chamber Analysis)[87, 88] - Aldeyra has entered into an exclusive option agreement with AbbVie Inc for license to develop and commercialize Reproxalap, including a potential upfront payment of $100 million less option fees, a $100 million milestone payment upon U S FDA approval in dry eye disease, and $200 million in additional regulatory and commercial milestones[95, 97]

Business Highlights - The company's customer numbers increased by 156% year-over-year (YoY) and 24% quarter-over-quarter (QoQ)[8] - Annual Recurring Revenue (ARR) reached RMB 5370万 in September 2025, representing a YoY growth of over 160%[9] - EngageLab's customers span 52 countries and regions, with offices established in Hong Kong, Singapore, Malaysia, and Japan[12] - GPTBots.ai entered a strategic partnership with Vonosis Co, Ltd in Thailand to deliver localized AI solutions[15] - EngageLab upgraded its Marketing Automation functions with AI-powered capabilities to enhance marketing efficiency and user conversion rates[18] Financial Highlights - The company achieved GAAP net income for two consecutive quarters, a historic first[29, 33] - Q3 2025 recorded the highest quarterly revenue in EngageLab's history[29] - Net Dollar Retention (NDR) for Developer Services (Subscription) reached 104%, the highest level in history[29, 53] - Total revenue reached RMB 9090万, a 15% YoY increase and 1% QoQ increase[36] - Gross profit increased by 20% YoY and 7% QoQ, reaching RMB 6380万, the highest level in the past 15 quarters, with a gross margin of 702%[30, 46] - Deferred revenue reached RMB 16630万, a historic high[30, 50, 53]

Financial Performance - Okeanis Eco Tankers achieved a fleetwide TCE of $46,600 per day in Q3 2025[16], compared to $57,700 in Q3 2024[16] - Adjusted EBITDA for Q3 2025 was $45.2 million[16], and $124.9 million for the first 9 months of 2025[16] - Adjusted earnings per share (EPS) for Q3 2025 was $0.77[17], and $1.95 for the first 9 months of 2025[16] - The company declared a dividend of $0.75 per share for the quarter[18] Balance Sheet - Total debt stood at $616.6 million[16] - Total cash was $58.2 million[16] - Total assets amounted to $1,067.1 million[16] - Total equity was $429.8 million[16], resulting in a book leverage of 57%[16] Commercial Strategy - 80% of available VLCC spot days for Q4 2025 were fixed at $88,100 per day[41] - 48% of available Suezmax spot days for Q4 2025 were fixed at $60,800 per day[41]

Financial Highlights - The company's revenue in 2025E is projected to be $1.8 billion[9] - The company projects year-over-year revenue growth of $278 million, a 17.8% increase at the midpoint[56] - Adjusted EBITDA for 2025 is guided to be between $415 million and $425 million, representing a $59 million increase, or 16.5% at the midpoint[56] - Adjusted Free Cash Flow is expected to be between $170 million and $180 million, an increase of $16.7 million, or 10.5% at the midpoint[56] - Net cash provided by operating activities is projected to be between $325 million and $335 million, up $48.6 million, or 17.3% at the midpoint[56] Business Operations - Collection services account for 64.7% of the company's revenue[6] - Disposal services contribute 14.6% to the company's revenue[6] - National Accounts represent 12.1% of the company's revenue[6] - Resource Solutions Processing accounts for 7.5% of the company's revenue[6] - Energy & Processing contributes 1.0% to the company's revenue[6] Strategic Initiatives - The company has completed 66 acquisitions since 2019, deploying approximately $2 billion of capital to acquire approximately $850 million of annual revenue[27]

La Guitarra Mine Operations & Expansion - Full commercial production at La Guitarra Mine commenced on January 1, 2025[13, 27] - Q3 2025 sales reached 153,583 silver equivalent ounces[13] - Q3 2025 revenues totaled $5.5 million[13] - Gross profit for Q3 2025 was $1.7 million[13, 47] - A C$19.5 million private placement closed in July 2025 to fund plant expansion[13, 40] - Expansion plans aim to increase capacity by +50% to 750-800 tonnes per day by Q2 2026 and +100% to 1,200-1,500 tonnes per day by Q3 2027[48, 49, 51] La Guitarra Resource Estimate - The 2023 resource update shows 272 million silver-equivalent Measured & Indicated ounces, a 373% increase[31] - Inferred resources are 202 million silver-equivalent ounces, a 204% increase[31] Tepic Project Exploration - Exploration at Tepic Project indicates a potential strike length of over 15 km[75, 76] - Historical ore shoots in the East District measure up to 750 meters in length and 1-4 meters in thickness[57] Financials & Share Structure - Current assets, including cash, were $16.9 million as of September 30, 2025[84, 93] - A $5 million loan from First Majestic Silver bears interest at 15% per annum[64, 71, 84]

DarioHealth Corp. The innovative, scalable platform for cost efficient, whole-body health November 2025 Forward-Looking Statement This presentation of DarioHealth Corp. ("Dario", the "Company", "we" and "our") and statements of our management or agents related thereto contain or may contain forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements which are not historical reflect our current expectations and projections about our future re ...

Operational & User Growth - Bilibili's MAUs reached 376 million[5] - Bilibili's DAUs reached 117 million[5], a 9% year-over-year increase[7] - Average daily time spent per user increased to 112 minutes[5], a 6% year-over-year increase[7] Financial Performance - Bilibili's net revenue reached RMB 7685 million[55] in 25Q3, a 5% year-over-year increase[68] - Gross profit margin improved to 36.7%[9] - Adjusted net profit was RMB 786 million[9], a 233% year-over-year increase[9] Revenue Breakdown - Value-added services revenue was RMB 3023 million[36], a 7% year-over-year increase[68], contributing 39% to total revenue[55] - Advertising revenue was RMB 2570 million[45], a 23% year-over-year increase[45], accounting for 33% of total revenue[55] - Mobile games revenue was RMB 1511 million[68], a 17% year-over-year decrease[68], representing 20% of total revenue[55] - IP derivatives and others revenue was RMB 581 million[68], a 3% year-over-year increase[68], making up 8% of total revenue[55] User Demographics - Bilibili has unparalleled leadership in China's young generation[15] - 7 out of 10 Gen Z+ (1985-2009) population in China are Bilibili users[15]

Company Overview - enCore Energy is positioned as the largest ISR uranium extractor in the United States, with operations underway at two plants[14] - The company has significant S-K 1300 resources, including 30.94 million pounds in the Measured and Indicated (M&I) category and 20.54 million pounds in the Inferred category[19] - enCore Energy's market capitalization was approximately $598.85 million as of October 31, 2025, with 187,139,534 shares issued and outstanding[52] Uranium Market and Strategy - The United States faces a growing demand for uranium, with demand increasing by +48 million pounds per year, while domestic supply is declining by -200,000 pounds per year[45] - The company employs a uranium sales strategy supported by sales agreements while preserving exposure to the market[22] - Current contracts represent less than 38% of planned extraction through 2033, allowing for significant upside exposure to spot market pricing[184] Project Pipeline and Production - Alta Mesa CPP commenced operations in Q2 2024 and is configured to operate at 1 million lbs per year, currently running at 60% of that capacity[131] - Daily production at Alta Mesa averaged 2,678 pounds per day in June 2025[136] - The Dewey Burdock ISR Uranium Project has measured resources of 14,285,988 lbs and indicated resources of 2,836,159 lbs of U₂O₃[166]

JD.com, Inc. Financial and Operational Highlights Nov 2025 This document does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge tha ...